Alphavirus vectors for gene expression and vaccines

Current Opinion in Biotechnology

Volumn 10, Issue 5, 1999, Pages 434-439

  Schlesinger, Sondra ^a   Dubensky Jr , Thomas W ^b  

^a W ^*  (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ALPHA VIRUS; ASSAY; CELL LINE; DIAGNOSIS; EXPRESSION VECTOR; HIPPOCAMPUS; NERVE CELL; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVIEW; SINDBIS VIRUS; VACCINE PRODUCTION;

EID: 0032859384     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00006-3     Document Type: Review

References (30)

1. Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesinger S, Rice CM Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA. 93:1996;11371-11377.
2. Lundstrom K Alphaviruses as expression vectors. Curr Opin Biotechnol. 8:1997;578-582.
3. Garoff H, Li KJ Recent advances in gene expression using alphavirus vectors. Curr Opin Biotechnol. 9:1998;464-469.
4. Frolov I, Frolova E, Schlesinger S Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA. J Virol. 71:1997;2819-2829.
5. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 239:1997;389-401.
6. •].
7. •] established cell lines showing the feasibility of large-scale production of packaged replicons.
8. Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol. 15:1997;763-767.
9. Iijima Y, Ohno K, Ikeda H, Sawai K, Levin B, Meruelo D Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Int J Cancer. 80:1999;110-118.
10. Dryga SA, Dryga OA, Schlesinger S Identification of mutations in a Sindbis virus variant able to establish persistent infection in BHK cells: the importance of a mutation in the nsP2 gene. Virology. 228:1997;74-83.
11. ••].
12. ••] describe noncytopathic Sindbis virus replicons. They include some applications but also the limitation that their use may be restricted to certain cell lines.
13. Olivo PD, Collins PL, Peeples ME, Schlesinger S Detection and quantitation of human respiratory syncytial virus (RSV) using minigenome cDNA and a Sindbis virus replicon: a prototype assay for negative-strand RNA viruses. Virology. 251:1998;198-205. An example in which noncytopathic replicons were used to develop an assay for respiratory syncytial virus.
14. Ivanova L, Schlesinger S, Olivo PD Regulated expression of a Sindbis virus replicon by herpesvirus promoters. J Virol. 73:1999;1998-2005. This paper shows how a Sindbis virus replicon can be used to detect herpesviruses. It also describes a cell line that can be induced by HSV-1 to produce packaged replicons.
15. ••].
16. ••] show that alphavirus replicons can be used as expression vectors in rat hippocampal slice cultures and may be of value for neurophysiological studies.
17. Lundstrom K Alphaviruses as tools in neurobiology and gene therapy. J Recept Signal Transduct Res. 19:1999;673-686.
18. •].
19. •] establish that alphavirus replicons used as DNA plasmids are very effective and much better than conventional plasmids when used to immunize mice and protect them against infection.
20. Berglund P, Fleeton MN, Smerdou C, Liljeström P Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine. 17:1999;497-507.
21. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 251:1998;28-37. These authors show that cynomolgus macaques vaccinated with Venezuelan equine encephalitis replicons expressing a glycoprotein subunit from Marburg virus will be protected against a challenge with the virus.
22. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljeström P Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses. 13:1997;1487-1495.
23. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, Johnston RE Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol. 71:1997;3031-3038.
24. Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny Aet al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol. 70:1996;1953-1960.
25. Davis NL, Brown KW, Johnston RE A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol. 70:1996;3781-3787.
26. Albert ML, Sauter B, Bhardwaj N Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1988;86-89.
27. Hahn YS, Guanzon A, Rice CM, Hahn CS Class I MHC molecule mediated inhibition of Sindbis virus replication. J Immunol. 162:1999;69-77. This paper demonstrates that the growth of at least one strain of Sindbis virus can be restricted in mouse cells depending on the H-2 haplotype. It is not known what, if any, haplotype restrictions there are in human cells.
28. Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, Nussenzweig RS, Zavala F Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol. 72:1998;6907-6910.
29. Colombage G, Hall R, Pavy M, Lobigs M DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology. 250:1998;151-163.
30. Malone JG, Bergland PJ, Liljeström P, Rhodes GH, Malone RW Mucosal immune responses associated with polynucleotide vaccination. Behring Inst Mitt. 98:1997;63-72.